Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis

OBJECTIVES: Skin fibrosis mediated by activated dermal fibroblasts is a hallmark of systemic sclerosis (SSc), especially in the subset of patients with diffuse disease. Transforming growth factor-beta (TGFβ) and interleukin-6 (IL-6) are key candidate mediators in SSc. Our aim was to elucidate the sp...

Descripción completa

Detalles Bibliográficos
Autores principales: Denton, Christopher P, Ong, Voon H, Xu, Shiwen, Chen-Harris, Haiyin, Modrusan, Zora, Lafyatis, Robert, Khanna, Dinesh, Jahreis, Angelika, Siegel, Jeffrey, Sornasse, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Basic and Translational Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104680/
https://www.ncbi.nlm.nih.gov/pubmed/29853453
http://dx.doi.org/10.1136/annrheumdis-2018-213031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104680/
https://www.ncbi.nlm.nih.gov/pubmed/29853453
http://dx.doi.org/10.1136/annrheumdis-2018-213031

Ejemplares similares